Skip to content
Triangle logo TriangleGet started
← Hodgkin Lymphoma

HEALTH PROFESSIONAL · SOURCE READING

Treatment Options for Recurrent Classic HL

Source: Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment of Recurrent Classic HL

Treatment options for recurrent classic HL include:

Pembrolizumab or nivolumab (alone or with chemotherapy).

Source links and citations

Brentuximab vedotin.

Source links and citations

Brentuximab vedotin plus nivolumab.

Source links and citations

Chemotherapy with stem cell transplant.

Source links and citations

Combination chemotherapy.

Source links and citations

Radiation therapy.

Source links and citations

Continue within this section

Pembrolizumab or nivolumab (alone or with chemotherapy) →Brentuximab vedotin →Brentuximab vedotin plus nivolumab →Chemotherapy with stem cell transplant →Combination chemotherapy →Radiation therapy →Summary for sequencing therapies for recurrent classic HL →

Preserved source evidence · Not medical advice